Education
About Us
Working with TipRanks
Follow Us
TMS Co., Ltd. (JP:4891)
:4891
4891 Stock Chart & Stats
¥129.00
-¥1.00(-0.47%)
At close: 4:00 PM EST
¥129.00
-¥1.00(-0.47%)
Day’s Range― - ―
52-Week Range¥120.00 - ¥209.00
Previous CloseN/A
Volume100.70K
Average Volume (3M)256.91K
Market Cap
¥6.50B
Enterprise Value¥3.15B
Total Cash (Recent Filing)¥3.18B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Jul 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,485,767
10 Day Avg. Volume257,770
30 Day Avg. Volume256,913
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-15.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetZero reported debt materially lowers solvency risk and preserves strategic optionality. Without interest burdens, management can prioritize R&D or milestone spending, extend runway during development cycles, and better withstand biotech-sector funding volatility.
Past Demonstrated Cash-generation AbilityRobust FY2022 operating and free cash flow (~¥1.26bn) evidences the business or its assets can generate meaningful cash in the right conditions. That historical capability suggests the company has routes to monetize technology or operations if execution and market conditions improve.
Lean Operating StructureA headcount of 14 indicates a lean, low-fixed-cost model that reduces ongoing cash burn while advancing development. For a pre-commercial biotech, a small team can extend runway, maintain capital efficiency, and enable focused spending on high-priority milestones.
Bears Say
Multi-year Zero RevenueThree consecutive fiscal years with zero revenue means the company lacks demonstrated commercial traction. Prolonged no-revenue periods increase execution risk for product launches or partnerships and make ongoing operations highly dependent on external financing or one-time asset monetization.
Persistent Losses And Capital ErosionSignificant ongoing losses (FY2025 -¥661m) and falling equity signal capital erosion and negative returns on invested capital (FY2025 ROE ~-23%). This weakens balance sheet resilience, raises refinancing or dilution risk, and constrains the firm's ability to fund development internally.
Negative Operating And Free Cash FlowContinued negative operating and free cash flow in FY2025 indicates persistent cash burn and ongoing funding needs. Even with some improvement versus prior year, sustained negative cash generation necessitates external capital or partnerships, increasing execution risk and potential shareholder dilution.
TMS Co., Ltd. News
4891 FAQ
What was TMS Co., Ltd.’s price range in the past 12 months?
TMS Co., Ltd. lowest stock price was ¥120.00 and its highest was ¥209.00 in the past 12 months.
What is TMS Co., Ltd.’s market cap?
TMS Co., Ltd.’s market cap is ¥6.50B.
When is TMS Co., Ltd.’s upcoming earnings report date?
TMS Co., Ltd.’s upcoming earnings report date is Jul 10, 2026 which is in 123 days.
How were TMS Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is TMS Co., Ltd. overvalued?
According to Wall Street analysts TMS Co., Ltd.’s price is currently Overvalued.
Does TMS Co., Ltd. pay dividends?
TMS Co., Ltd. does not currently pay dividends.
What is TMS Co., Ltd.’s EPS estimate?
TMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TMS Co., Ltd. have?
TMS Co., Ltd. has 45,485,767 shares outstanding.
What happened to TMS Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4891
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TMS Co., Ltd.
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.